In Vivo Model Development for Lymphoma

Protheragen offers a comprehensive in vivo Lymphoma animal model development service, designed to accelerate the translational research and preclinical evaluation of novel therapeutics. Leveraging an extensive portfolio of validated murine models, we deliver scientifically robust and customized solutions to support the discovery, efficacy assessment, and mechanistic study of anti-lymphoma agents.

Animal models are fundamental to advancing our understanding of lymphoma pathogenesis and to the preclinical development of effective therapies. At Protheragen, we utilize Mus musculus (mouse) as the primary species, offering a broad selection of strains including Balb/c, C57BL/6, NSG, NOG, SCID, NOD, and others. These strains encompass immunocompetent, immunodeficient, and transgenic backgrounds, enabling modeling of both human and murine lymphomas. Our models include xenografts, allografts, syngeneic, and patient-derived xenografts (PDX), capturing the genetic, phenotypic, and microenvironmental complexity of lymphoma as seen in human disease. This diversity allows us to address a wide range of research needs, from basic mechanistic studies to the evaluation of targeted and immunotherapeutic strategies.

Xenograft Models

Xenograft models involve the transplantation of human or murine lymphoma cells into immunodeficient mice, such as NSG, NOG, SCID, or nude strains. Cells may be derived from established cell lines or directly from patient tumors (PDX). This methodology enables the study of tumor growth, metastasis, and drug response in a living organism. Key advantages include high translational relevance, the ability to evaluate human-specific therapeutics, and flexibility in modeling various genetic subtypes. Xenograft models are primarily used for efficacy testing of novel agents, biomarker validation, and exploration of tumor-host interactions.

Syngeneic and Allograft Models

Syngeneic models utilize the transplantation of murine lymphoma cells into immunocompetent mice of the same genetic background, while allograft models involve genetically distinct but same-species donors and recipients. This approach preserves an intact immune system, allowing for the assessment of immune-mediated mechanisms and immunotherapy strategies. Advantages include reproducibility, cost-effectiveness, and suitability for immuno-oncology research. These models are widely used to study tumor immunology, evaluate immune checkpoint inhibitors, and investigate combination therapies.

Genetically Engineered and Transgenic Models

Genetically engineered mouse models (GEMMs) and transgenic strains are developed by introducing specific oncogenes, fusion proteins, or gene knockouts/knockins relevant to lymphoma pathogenesis (e.g., Myc, Bcl2, PDCD1, NR1I3). These models recapitulate spontaneous lymphoma development, genetic heterogeneity, and disease progression as seen in patients. The main advantages are physiological disease development, faithful modeling of genetic drivers, and suitability for studying tumor initiation, progression, and resistance mechanisms. GEMMs are essential for dissecting molecular pathways and validating therapeutic targets.

Protheragen provides an end-to-end solution for in vivo lymphoma model development and preclinical testing. Our services include model selection or custom development, cell line or PDX engraftment, study design, dosing and treatment administration, and comprehensive endpoint analysis. Key efficacy endpoints include tumor volume measurement, survival analysis, bioluminescence imaging, flow cytometry, histopathology, and molecular biomarker assessment (e.g., immunohistochemistry, PCR, ELISA). Our analytical capabilities extend to pharmacokinetic/pharmacodynamic profiling, immune cell phenotyping, and mechanistic studies. Rigorous quality control measures are implemented at every stage, including genetic authentication, pathogen screening, and adherence to standardized protocols, ensuring data reliability and reproducibility.

Partnering with Protheragen gives you access to a scientifically rigorous, highly adaptable, and client-focused preclinical platform for lymphoma research. Our expertise, comprehensive model repertoire, and commitment to quality ensure reliable results that accelerate your drug development pipeline. Contact us today to discuss your project needs and discover how Protheragen can help advance your lymphoma research objectives.